| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Division of Molecular Pathology,* Memorial Sloan-Kettering Cancer Center, New York; the Departments of Molecular Genetics and Pathology and the Seaver Center for Bioinformatics, Albert Einstein College of Medicine, Bronx; the Department of Physiology and Biophysics, Mt. Sinai School of Medicine, New York; and the Center for Genomics and Human Genetics, North Shore-Long Island Jewish Research Institute, Manhasset, New York
To identify gene expression changes along progression of bladder cancer, we compared the expression profiles of early-stage and advanced bladder tumors using cDNA microarrays containing 17,842 known genes and expressed sequence tags. The application of bootstrapping techniques to hierarchical clustering segregated early-stage and invasive transitional carcinomas into two main clusters. Multidimensional analysis confirmed these clusters and more importantly, it separated carcinoma in situ from papillary superficial lesions and subgroups within early-stage and invasive tumors displaying different overall survival. Additionally, it recognized early-stage tumors showing gene profiles similar to invasive disease. Different techniques including standard t-test, single-gene logistic regression, and support vector machine algorithms were applied to identify relevant genes involved in bladder cancer progression. Cytokeratin 20, neuropilin-2, p21, and p33ING1 were selected among the top ranked molecular targets differentially expressed and validated by immunohistochemistry using tissue microarrays (n = 173). Their expression patterns were significantly associated with pathological stage, tumor grade, and altered retinoblastoma (RB) expression. Moreover, p33ING1 expression levels were significantly associated with overall survival. Analysis of the annotation of the most significant genes revealed the relevance of critical genes and pathways during bladder cancer progression, including the overexpression of oncogenic genes such as DEK in superficial tumors or immune response genes such as Cd86 antigen in invasive disease. Gene profiling successfully classified bladder tumors based on their progression and clinical outcome. The present study has identified molecular biomarkers of potential clinical significance and critical molecular targets associated with bladder cancer progression.
This article has been cited by other articles:
 |
|
 |
|
  M. R. Saban, J. M. Backer, M. V. Backer, J. Maier, B. Fowler, C. A. Davis, C. Simpson, X.-R. Wu, L. Birder, M. R. Freeman, et al. VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation Am J Physiol Renal Physiol, July 1, 2008; 295(1): F60 - F72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Devany, F. Kappes, K.-M. Chen, D. M. Markovitz, and H. Matsuo Solution NMR structure of the N-terminal domain of the human DEK protein Protein Sci., February 1, 2008; 17(2): 205 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hurtado, J. J. Lozano, E. Castellanos, L. A Lopez-Fernandez, K. Harshman, C. Martinez-A, A. R Ortiz, T. M Thomson, and R. Paciucci Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells Gut, September 1, 2007; 56(9): 1266 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matsui, M. Ito, H. Nishiyama, H. Uno, H. Kotani, J. Watanabe, P. Guilford, A. Reeve, M. Fukushima, and O. Ogawa Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models Bioinformatics, March 15, 2007; 23(6): 732 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Wise-Draper, H. V. Allen, E. E. Jones, K. B. Habash, H. Matsuo, and S. I. Wells Apoptosis Inhibition by the Human DEK Oncoprotein Involves Interference with p53 Functions Mol. Cell. Biol., October 15, 2006; 26(20): 7506 - 7519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Ellis The role of neuropilins in cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1099 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanchez-Carbayo, N. D. Socci, J. Lozano, F. Saint, and C. Cordon-Cardo Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays J. Clin. Oncol., February 10, 2006; 24(5): 778 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanchez-Carbayo, N. D. Socci, J. J. Lozano, B. B. Haab, and C. Cordon-Cardo Profiling Bladder Cancer Using Targeted Antibody Arrays Am. J. Pathol., January 1, 2006; 168(1): 93 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Wild, A. Herr, C. Wissmann, R. Stoehr, A. Rosenthal, D. Zaak, R. Simon, R. Knuechel, C. Pilarsky, and A. Hartmann Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder Clin. Cancer Res., June 15, 2005; 11(12): 4415 - 4429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Blaveri, J. P. Simko, J. E. Korkola, J. L. Brewer, F. Baehner, K. Mehta, S. DeVries, T. Koppie, S. Pejavar, P. Carroll, et al. Bladder Cancer Outcome and Subtype Classification by Gene Expression Clin. Cancer Res., June 1, 2005; 11(11): 4044 - 4055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eschrich, I. Yang, G. Bloom, K. Y. Kwong, D. Boulware, A. Cantor, D. Coppola, M. Kruhoffer, L. Aaltonen, T. F. Orntoft, et al. Molecular Staging for Survival Prediction of Colorectal Cancer Patients J. Clin. Oncol., May 20, 2005; 23(15): 3526 - 3535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ohlsson, J. M. A. Moreira, P. Gromov, G. Sauter, and J. E. Celis Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas Mol. Cell. Proteomics, April 1, 2005; 4(4): 570 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Maruya, H.-W. Kim, R. S. Weber, J. J. Lee, M. Kies, M. A. Luna, J. G. Batsakis, and A. K. El-Naggar Gene Expression Screening of Salivary Gland Neoplasms: Molecular Markers of Potential Histogenetic and Clinical Significance J. Mol. Diagn., August 1, 2004; 6(3): 180 - 190. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Evans, B. L. Gallie, M. A.S. Jewett, G. R. Pond, K. Vandezande, J. Underwood, Y. Fradet, G. Lim, P. Marrano, M. Zielenska, et al. Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction Am. J. Pathol., January 1, 2004; 164(1): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
